Zhidkova I A, Karlov V A, Vlasov P N
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(9. Vyp. 2):82-88. doi: 10.17116/jnevro20161169282-88.
To analyze the efficacy and tolerability of the innovative drug perampanel (PER) as add-on treatment of focal epilepsy in patients older than 12 years.
Forty-six patients with focal epilepsy, aged from 12 to 63 years, mean age 31.7 years, were studied.
A decrease in the frequency of all types of seizures by >50% was noted in 46,5% of patients. Stopping of all types of seizures was found in 25.6% of patients, i.e. in every fourth patient, stopping of secondary-generalized seizures in 39.5%. Adverse effects (AE) were identified in 13 (28.2%) of patients, including aggressiveness - 6 (13.0%); other AE were less frequent (<10%): sleepiness (8.7%), dizziness (4.3%), postural instability (4.3%), irritability (4.3%). PER was withdrawn in 3 (6.5%) patients due to AE. Mean effective dose was 6 mg/day. Quality-of-life improved in the majority of patients (71.7%).
分析创新药物吡仑帕奈（PER）作为12岁以上局灶性癫痫患者附加治疗的疗效和耐受性。
研究了46例局灶性癫痫患者，年龄在12至63岁之间，平均年龄31.7岁。
46.5%的患者所有类型癫痫发作频率降低>50%。25.6%的患者所有类型癫痫发作停止，即每四名患者中有一名；39.5%的患者继发性全面性癫痫发作停止。13例（28.2%）患者出现不良反应（AE），包括攻击性6例（13.0%）；其他AE较少见（<10%）：嗜睡（8.7%）、头晕（4.3%）、姿势不稳（4.3%）、易怒（4.3%）。3例（6.5%）患者因AE停用PER。平均有效剂量为6毫克/天。大多数患者（71.7%）的生活质量得到改善。
